AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01117285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined implementation strategy
Description: The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.~OTs receive:~* 3-day post-graduate course~* 2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.~* Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.~* Discussion platform~* Web-based registration system: Provides guidance in using the COTiD program for every individual client.~* Regional meetings: successes and difficulties in using the COTiD are discussed.~Managers and physicians receive:~* Information on the COTiD program through a website and newsletters.~* Motivational reminders.
Study NCT02529605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Product B® IsaGenesis®
Description: This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
Study NCT02529605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IsaGenesis®
Description: This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
Study NCT02769130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan is given for 12 months
Study NCT02162823 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreatic Surgery
Description: Surgical removal of the pancreatic tumour (cancer) in the intervention group
Study NCT01792505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine in combination with Imiquimod cream
Description: After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
Study NCT03511599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation
Study NCT03511599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation
Study NCT03511599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet matched to cycloserine tab
Study NCT01284010 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Study NCT02659020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV
Study NCT02659020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV
Study NCT02659020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Administered IV
Study NCT02659020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT02035852 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: 3T MRI vs. 7T MRI
Study NCT04440956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SARTATE
Description: 200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms.
Study NCT02901951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.
Study NCT01971853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
Study NCT01971853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Analgesics
Description: Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
Study NCT01944774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Description: IV Infusion, once daily for 7\~14 days
Study NCT01944774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 650 mg
Description: IV Infusion, once daily for 7\~14 days
Study NCT01944774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: IV Infusion, once daily for 7\~14 days
Study NCT01351675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once daily
Study NCT01284010 — intervention group
Intervention type: GENETIC
Intervention: fluorescence in situ hybridization
Study NCT01284010 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Study NCT01284010 — intervention group
Intervention type: GENETIC
Intervention: microarray analysis
Study NCT01284010 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Study NCT01284010 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Study NCT01284010 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT03893643 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention in an observational study
Study NCT01027598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib: 600 mg orally daily
Study NCT01027598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib: 150 mg orally daily
Study NCT01027598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib: 150 mg orally daily
Study NCT01351675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl: 20 mg
Description: 20 mg, oral, once daily
Study NCT01039909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Study NCT01039909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Study NCT00483938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
Study NCT02493231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam
Study NCT02493231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT02493231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT01710631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone 3 mg
Description: eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
Study NCT01710631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03945149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmipure Gold™
Description: 30 subjects will take 1000mg in 4 capsules (with 250ml water before breakfast , each day, during 5 weeks
Study NCT03945149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 subjects will take 4 capsules with 250ml water before breakfast , each day, during 5 weeks
Study NCT03691571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Cooling
Description: The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.
Study NCT03691571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of care involves standard temperature probe monitoring.
Study NCT02481817 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic dilation of subglottic stenosis
Description: This is accomplished with rigid instruments or inflatable balloons.
Study NCT02481817 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic resection of the stenosis
Description: This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
Study NCT02481817 — intervention group
Intervention type: PROCEDURE
Intervention: Tracheal Resection
Description: Resection of the affected tracheal segment with end-to-end anastomosis
Study NCT01643824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: - Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 \<40%, and/or RLV30 \<30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30\<50% and RLV30\<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30\<60%, and/or RLV30\<50%~- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV
Study NCT02831517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm
Study NCT02831517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched Placebo
Study NCT01278797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine Combination Tablet
Description: Combination Tablet
Study NCT01278797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Monocomponent
Description: Active Comparator
Study NCT04326049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLETZ with videocolposcope
Description: Loop procedure using a videocolposcope in order to see and remove the abnormal cervical tissue
Study NCT04326049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ with binocular colposcope
Description: Loop procedure using a binocular colposcope in order to see and remove the abnormal cervical tissue
Study NCT01258283 — intervention group
Intervention type: OTHER
Intervention: Addional imaging
Description: All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
Study NCT00839761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron fortified rice
Study NCT00839761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: iron drops
Study NCT00856804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
Study NCT00496288 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic radiation to the contralateral breast
Description: The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
Study NCT01726985 — intervention group
Intervention type: OTHER
Intervention: Parameter Based Clinical Disposition
Description: Parameter Based Clinical Disposition'~Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:~* NT-ProBNP reduction of > 23% from peak value during admission~* Fluid Reduction of > 1.3L (orders for I/O q8h required)~* Serum Sodium of > 135 mmol/L the day of planned discharge
Study NCT03300063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low flow nocturnal oxygen
Description: Nocturnal low-flow oxygen via nasal cannula
Study NCT03238833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: luteal ovarian stimulation
Description: In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.
Study NCT03238833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: follicular ovarian stimulation
Description: In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.
Study NCT02518373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Description: G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.
Study NCT02518373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
Study NCT01755728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
Study NCT01755728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
Study NCT01417481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glycine
Description: Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
Study NCT01755728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of PDA
Description: Open surgery for closure of PDA
Study NCT02701933 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
Study NCT02701933 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Saline, intravenous infusion
Study NCT02492321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005
Study NCT02492321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT05191927 — intervention group
Intervention type: OTHER
Intervention: male
Description: Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
Study NCT01417481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
Study NCT01298011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Abraxane
Description: 3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
Study NCT01273012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic - Infloran
Description: Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
Study NCT01273012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic - Infloran
Description: Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
Study NCT00408408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg IV
Study NCT02343809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actual Diacutaneous Fibrolysis
Description: Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
Study NCT02343809 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Diacutaneous Fibrolysis
Description: Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
Study NCT02343809 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Protocolized Physiotherapy
Description: Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
Study NCT02343809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized Physiotherapy
Description: Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
Study NCT02343809 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Protocolized Physiotherapy
Description: Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
Study NCT03736876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: About Us
Description: Each program session includes an initial soap opera-like story to build interest and illustrate key concepts, 2-3 group-based activities with reflection, individual app-based work on tablets to allow for personalization of the content, and a group-based debrief to reflect on the day and reinforce key messages. The group-based content is delivered by trained facilitators from the participating school-based health centers. The app-based content is housed on a secure website and accessed through tablets with unique log-ins for each participant. Activities are completed individually during the session (e.g., completing a poll; watching and responding to a brief video). Several lessons include homework activities that encourage communication between students and a caring adult.
Study NCT01359501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese medical treatment-LCH1
Description: Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
Study NCT01359501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
Study NCT00408408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825 mg/m2 orally
Study NCT03508609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS16
Description: GCSF-mobilized autologous CD34 cells
Study NCT02922179 — intervention group
Intervention type: DRUG
Intervention: Long- and intermediate- acting insulins
Description: alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
Study NCT01679886 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Rubidium PET
Description: Rubidium PET
Study NCT00345618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux sodium
Description: 0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection
Study NCT00345618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration
Study NCT00345618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for idrabiotaparinux sodium)
Description: 0.5 mL pre-filled syringe~Subcutaneous injection
Study NCT00345618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avidin
Description: 100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes
Study NCT00345618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avidin
Description: 100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes
Study NCT00345618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for warfarin)
Description: Warfarin matching capsules~Oral administration
Study NCT00345618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Prefilled syringes as locally registered~Subcutaneous injection
Study NCT00345618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Prefilled syringes as locally registered~Subcutaneous injection
Study NCT00250276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
Study NCT00667849 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exogen 4000+
Description: Low-intensity pulsed ultrasound (LIPUS)